No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VIR Vir Biotechnology
- 8.950
- -0.230-2.51%
Close Jun 18 16:00 ET
- 8.903
- -0.047-0.53%
Post 19:54 ET
1.22BMarket Cap-2231P/E (TTM)
9.150High8.910Low1.02MVolume9.100Open9.180Pre Close9.15MTurnover1.12%Turnover RatioLossP/E (Static)136.06MShares25.37052wk High0.79P/B813.85MFloat Cap7.61052wk Low--Dividend TTM90.93MShs Float141.010Historical High--Div YieldTTM2.61%Amplitude7.610Historical Low8.991Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Vir Biotechnology(VIR.US) Director Sells US$43,789.2 in Common Stock
$Vir Biotechnology(VIR.US)$ Director Ramasastry Saira sold 4,000 shares of common stock on Jun 11, 2024 at an average price of $10.9473 for a total value of $43,789.2.Source: Announcement What is stat
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the
Form 144 | Vir Biotechnology(VIR.US) Director Proposes to Sell 474.39K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 7, $Vir Biotechnology(VIR.US)$ Director PEREZ ROBERT J intends to sell 42,377 shares of its common stock on Jun 7, with a total market value of approximately $474.39K. S
Vir Biotechnology Is Maintained at Equal-Weight by Morgan Stanley
Vir Biotechnology Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Vir Biotechnology, Raises Price Target to $15
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Equal-Weight and raises the price target from $12 to $15.
Comments
$Vir Biotechnology(VIR.US$ Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization
1
6
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
11
2
$Vir Biotechnology(VIR.US$ They need better cost control and accounting practice to boost share price to a reasonable level (say 20). Section is bad because of Biden, but literally science is priced at 0 for VIR. Active investor should interfere. I’ll vote all Against in proxy, as I am not happy at all.
1
. I bought more near support 7.8 (need to fight together with other bulls) will buy more if going down to support.$Vir Biotechnology(VIR.US$ small scale experiments are good.
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
QianmengYu : Need this push to make a bottom and back to a fair price say 20. This treatment is good, has similar negative rate comparing to Hepcludrex (GILD) bought ). It confirms this company has a real science. But not miracle…
TrytosaveabitOP QianmengYu: Can’t say I disagree at all! GL
QianmengYu TrytosaveabitOP: I added a little and will add more if there’s a dip. try to average down to 23 (top of big gap). This pretty babee really gave me huge loss.
TrytosaveabitOP QianmengYu: Gotcha! Yeah im afraid there will be a pullback before the next catalyst? Hope I’m wrong and it would just either consolidate after today a bit or start a steady uptrend. I just am not confident of that yet! Like MAIA! Was on a beautiful uptrend for over 10 days! Yesterday good news comes out and it’s now down about 30% or so from yesterday PM! Grrrr
QianmengYu TrytosaveabitOP: Yeah, I think there will be a pull back consolidation. consolidation makes uptrend longer (get ride of WSB gamblers)
View more comments...